Tychon Biosciences

Tychon Biosciences is a biotechnology company that specializes in developing a proprietary platform for the localized delivery of therapies to fibrotic tissues. The company's technology utilizes bispecific molecules designed to bind to collagen, the primary structural component of fibrotic scars, to concentrate therapeutic payloads at the site of disease. This targeted approach is intended to enhance efficacy while reducing systemic exposure and potential toxicity. Founded as a spin-out from Duke University, Tychon's research has primarily focused on addressing high-need areas in fibrotic diseases such as idiopathic pulmonary fibrosis. In July 2022, the company was acquired by Pliant Therapeutics, integrating its collagen-targeting platform into Pliant's broader fibrosis-focused portfolio.